Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT06066424 |
TitlePhase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) | Phase
Phase 1
|
Date Added 2023-10-04 |
Location
Texas, United States
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Cyclophosphamide, Fludarabine Phosphate, Rimiducid, TROP2-CAR-NK Cells |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06185556 |
TitleCOLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases | Phase
Phase 2
|
Date Added 2023-12-29 |
Location
Netherlands
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06218914 |
TitleA Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation | Phase
Phase 1
|
Date Added 2024-01-23 |
Location
California, United States
Florida, United States Illinois, United States Kansas, United States Missouri, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04853017 |
TitleELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201) | Phase
Phase 1
|
Date Added 2021-04-21 |
Location
California, United States
Colorado, United States Iowa, United States Massachusetts, United States Missouri, United States New York, United States Tennessee, United States Texas, United States |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Completed
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03990233 |
TitleA Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | Phase
Phase 1
|
Date Added 2019-06-18 |
Location
Belgium
France |
Prior IO Allowed Yes |
CRC-directed No |
Status
Completed
|
Drugs
BI 754091, BI 765063 |
Tags
MSS/ MMRp
|
| NCT ID NCT03412877 |
TitleAdministration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer | Phase
Phase 2
|
Date Added 2018-01-29 |
Location
Maryland, United States
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Aldesleukin, Cyclophosphamide, Fludarabine, Individual Patient TCR-Transduced PBL, Pembrolizumab (Keytruda) |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03530397 |
TitleA Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors | Phase
Phase 1
|
Date Added 2018-05-21 |
Location
Michigan, United States
New York, United States North Carolina, United States Rhode Island, United States Tennessee, United States Virginia, United States Australia France Italy Korea, Republic of Netherlands Portugal Spain Taiwan |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Carboplatin, MEDI5752, Pembrolizumab, Pemetrexed, Alimta, Imfinzi, Keytruda, Paraplatin |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03985891 |
TitleThe Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer | Phase
Phase 1/Phase 2
|
Date Added 2019-06-14 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Anti-PD-1 Monoclonal Antibody JS001, Chemotherapy |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03783403 |
TitleA Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers | Phase
Phase 1
|
Date Added 2018-12-21 |
Location
Alabama, United States
Arizona, United States California, United States Colorado, United States Missouri, United States New York, United States North Carolina, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia Canada France Italy Korea, Republic of Spain United Kingdom |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
CC-95251, cetuximab, Rituximab |
Tags
MSS/ MMRp
|
| NCT ID NCT01061515 |
TitleBiweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer | Phase
Phase 1
|
Date Added 2010-02-03 |
Location
Missouri, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Bevacizumab, capecitabine, Intraperitoneal Oxaliplatin, Avastin, Eloxatin, Xeloda |
Tags
MSS/ MMRp
|
